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Abstract: Since originally isolated in 1899, the genus Bifidobacterium has been demonstrated to
predominate in the gut microbiota of breastfed infants and to benefit the host by accelerating maturation
of the immune response, balancing the immune system to suppress inflammation, improving intestinal
barrier function, and increasing acetate production. In particular, Bifidobacterium longum subspecies
infantis (B. infantis) is well adapted to the infant gut and has co-evolved with the mother-infant dyad
and gut microbiome, in part due to its ability to consume complex carbohydrates found in human
milk. B. infantis and its human host have a symbiotic relationship that protects the preterm or term
neonate and nourishes a healthy gut microbiota prior to weaning. To provide benefits associated
with B. infantis to all infants, a number of commercialized strains have been developed over the past
decades. As new ingredients become available, safety and suitability must be assessed in preclinical
and clinical studies. Consideration of the full clinical evidence for B. infantis use in pediatric nutrition
is critical to better understand its potential impacts on infant health and development. Herein we
summarize the recent clinical studies utilizing select strains of commercialized B. infantis.
Keywords: Bifidobacterium longum subspecies infantis; B. infantis; probiotics; pediatric nutrition;
human milk oligosaccharides; inflammation; gut health; microbiome; short chain fatty acids; acetate
1. Introduction
The universal importance of bifidobacteria in human microbiota and gastrointestinal (GI) health
from infancy to advanced years (as reviewed [1]), including the critical role of genus Bifidobacterium in
the process of immune maturation early in life (as reviewed [2]), have been detailed in a wealth of
literature. Bifidobacteria are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive
bifid (i.e., “Y”) shape [3]. Genus Bifidobacterium was originally isolated from the stool of breastfed
infants in 1899, by Henri Tissier (as reviewed [2]). Bifidobacteria colonize the newborn gut within
the first days and weeks after birth and represent the most abundant bacterial genus ranging from
40% to 80% of the total gut microbiota [4,5]. Vertical transmission of bifidobacteria from the mother
(vagina, GI tract, or breast milk) has been demonstrated [6]. Vaginal delivery provides a higher
abundance of Bifidobacterium spp. in infants compared to caesarean section (C-section) delivery [7,8];
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however, the differences in the gut microbiomes of C-section and vaginally delivered neonates are not
apparent until day five of life [9]. Further, differences in Bifidobacterium spp. colonization between
vaginal and C-section delivery diminish by 30 days of age [10], highlighting the first month of life as
a critical period to establish colonization. Reduced abundance of Bifidobacterium spp. in infants has
been correlated to chronic diseases, including asthma and obesity [11], as well as to lower vaccine
response [12]. Henrick and colleagues postulated that loss of Bifidobacterium spp. in the infant gut
in populations of developed countries is linked to increased incidence of allergic and autoimmune
diseases [13]. Bifidobacterium spp. abundance can be further influenced by nutrition, antibiotic use,
and puberty [14–16]. Bifidobacterium longum subspecies infantis (B. infantis) in particular, dominates the
gut microbiota of breastfed infants and benefits the host by accelerating maturation of the immune
response, balancing the immune system to suppress inflammation, improving intestinal barrier function,
and increasing acetate production [17]. This symbiotic relationship is an example of coevolution
(humans and B. infantis) to protect the full term neonate and nourish a healthy gut microbiota prior to
weaning (as reviewed [18]).
Here, we focus on the current status of knowledge for B. infantis, including the preclinical data
and clinical evidence.
2. Current Status of Knowledge
2.1. Carbohydrate Metabolism and Short Chain Fatty Acids (SCFA) Production
Human milk oligosaccharides (HMO) are the primary substrate for B. infantis metabolism
(as reviewed [19]). HMO in human milk cannot be metabolized by the infant or by the majority of
bacteria in the infant gut, which lack the required enzymes necessary to access and metabolize complex
HMO. B. infantis demonstrates growth in vitro using HMO as the sole carbon source, reaching a cell
density 3-fold higher than B. longum subsp. longum, B. breve, B. bifidum, and B. adolescentis [20,21].
Once consumed by the infant, intact HMO transit through the infant stomach and proximal small
bowel, and are transported directly into the cytoplasm of B. infantis (Figure 1) to activate many genes
involved in catabolism of HMO (“HMO cluster”) [22]. Compared to other Bifidobacterium species,
the ability of B. infantis to sequester and facilitate complete digestion of HMO (via expression of up to
16 glycosyl hydrolases, such as α-fucosidases, β-galactosidases, β-hexosaminadases, and α-sialidases)
[22–24] provides a competitive advantage over other GI microbiota, including pathogens (Figure 2A).
Genes encoding carbohydrate transporters present in B. infantis also contribute to protection against
Escherichia coli O157:H7 [25]. Of importance, HMO utilization genes are conserved across all B. infantis
strains [26]. B. infantis preferentially consumes smaller HMO species (degree of polymerization <7)
which are consistently produced over the course of lactation and represent the bulk of HMO present in
pooled milk samples [27]. HMO metabolism by B. infantis produces short chain fatty acids (SCFA),
such as acetate, which provides an important role in nutrition and intestinal and immune development,
facilitates direct binding to intestinal cells, and stimulates anti-inflammatory/inhibits pro-inflammatory
cytokine release by intestinal cells [3,28,29]. Acetate produced by bacteria acts in vivo to promote the
defense functions of host epithelial cells [25]. Further acetate produced by B. infantis becomes a carbon
source that stimulates growth and function of butyrate-producing microbes [30]. Thus, HMO stimulate
the growth of bifidobacteria and by cross-feeding increase the production of butyrate, a preferred
energy source for colonocytes [31]. In addition to their role in the gut, SCFA produced by B. infantis
can enter circulation and directly affect the adipose tissue, lungs, brain, and liver, inducing overall
beneficial metabolic effects [31]. For example, a small fraction of acetate crosses the blood–brain barrier,
where it is taken up and activates hypothalamic neurons driving satiety [32], suggesting that acetate
has a direct role in central appetite regulation. Lactate also was shown to cross blood–brain barrier and
functions as an energy substrate of the brain [33].
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Figure 1. During breastfeeding, infant ingests human milk oligosaccharides (HMO) which allow selective 
growth of B. infantis in the lower gut. B. infantis thrives and dominates the gut of breastfed infant, providing 
numerous benefits important in healthy development. B. infantis is evolutionary unique in its ability to 
metabolize HMO and produce short chain fatty acids (SCFA). 
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Figure 2. Mechanisms of action of B. infantis: (A) B. infantis is equipped in “enzymatic machinery” to 
metabolize HMO, allowing increased colonization and fewer luminal pathogens via competitive advantage; 
(B) B. infantis produces exogenous substances that promote maturation of the immature innate immune 
Figure 2. Mechanisms of action of B. infantis: (A) B. infantis is equipped in “enzymatic machinery”
to metabolize HMO, allowing increased colonization and fewer luminal pathogens via competitive
advantage; (B) B. infantis produces exogenous substances that promote maturation of the immature
innate immune response in breastfed infants; (C) B. infantis has anti-inflammatory properties benefiting
the epithelial layer in the gut; (D) B. infantis reduces intestinal permeability and helps with “leaky gut”;
and (E) B. infantis produces SCFA (particularly acetate) which have a beneficial effect on the host.
Nutrients 2020, 12, 1581 5 of 18
Whereas other bacteria consume HMO (e.g., Bacteroidaceae), only Bifidobacteriaceae converts
HMO to acidic end products that affect stool pH [13]. Therefore, acidic fermentation of selected HMO
by B. infantis may result in fecal pH changes and reduction of dysbiotic taxa in the gut. Preclinical
models, including the necrotizing enterocolitis (NEC) model, have demonstrated that B. infantis could
potentially decrease intestinal permeability and increase stabilization of tight junction proteins [28,34].
For example, indole-3-lactic acid (ILA) is an anti-inflammatory molecule which significantly attenuates
lipopolysaccharide-induced activation of NF-κB in macrophages; it also attenuates an increase in the
pro-inflammatory cytokine IL-8. B. infantis contributes to maintaining the intestinal barrier integrity
through ILA, a metabolite of tryptophan [35], and may protect the epithelium via activation of the aryl
hydrogen receptor, which can further promote normal intestinal immune function. B. infantis could
also potentially protect against excessive intestinal inflammation which often affects the premature
infant and may be a contributing factor in NEC.
2.2. Proposed Mechanisms of Action of B. infantis Based on In Vitro Studies:
• B. infantis is highly specialized for the consumption of HMO and has a competitive advantage
against other bacteria, allowing increased colonization and resulting in fewer luminal pathogens
(Figure 2A) [36].
• B. infantis produces exogenous substances that promote maturation of the immature innate
immune response (Figure 2B) [28].
• HMO “turn on” the repertoire of genes in B. infantis that are important in controlling inflammation
within the infant gut (Figure 2C) [22].
• B. infantis becomes dominant in the gut and reduces pH by its unique ability to metabolize all
HMO into acidic end products, lactate, and acetate (Figure 2E) [36].
• B. infantis improves the intestinal barrier integrity through the production of tryptophan metabolite,
indole-3-lactic acid [35].
2.3. Clinical Evidence: Safety and Efficacy of Select Commercialized Strains of B. infantis Used in
Pediatric Populations
In 2007, the European Food Safety Authority (EFSA) assigned qualified presumption of safety
(QPS) status to the bacterial species B. longum, which includes subspecies infantis, indicating that this
taxonomic group does not raise any safety concerns [37]. The QPS status, which applies to all strains
of B. infantis listed in this review, indicates that none of those strains have been associated with human
clinical disease. In addition, based on our knowledge, B. infantis has not been associated with any
reports on antibiotic resistance. Here, we summarize clinical evidence for safety and efficacy of select
commercialized B. infantis strains used in pediatric populations (Table 1).
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Table 1. Clinical trials in pediatric populations using select strains of B. infantis.
B. infantis Strain
(Manufacturer) Trial ID Site Enrollment Feeding Period
Study Design/
Study Groups Study Outcomes Conclusions Year
M63
(Morinaga)
n/a France 66 infants 1 month Term infants identified with
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2.3.1. B. infantis M63
Term infants identified with colic were enrolled (n = 66) in a multicenter double-blind randomized
controlled trial (DBRCT); participants received a standard infant formula (IF) or an IF with added
probiotics (10 million CFU B. infantis M63 per 100 mL formula (Morinaga, Japan)) and 10 million
CFU Lactobacillus rhamnosus LCS742 per 100 mL formula [38]) over a one month feeding period.
Feeding-related GI adverse events were significantly lower in infants receiving M63. The same
probiotic mix was used in another DBRCT trial, where term infants (n = 97; <postnatal day (PND)
three of age) received M63 and LCS742 (140 million CFU per 100 mL formula, each) for six months [39].
After one month of feeding, infants receiving IF with added probiotics exhibited less crying or agitation
and more quiet behavior (p = 0.03) and at six months, atopic dermatitis was less frequently observed
(p < 0.05). Overall, the results from these two studies suggest the potential beneficial effect in a
population of children with colic as being improved tolerance and a protective effect against the
development of atopic dermatitis.
A probiotic mix of M63 (1 billion CFU/day), B. breve M16 (1 billion CFU/day), and B. longum BB536
(3 billion CFU/day) has been studied in several clinical trials. For example, children (n = 55, 4–12 years
of age) with functional constipation received polyethylene glycol (PEG, a laxative) or PEG and the
probiotic mix over an eight week period [40]. The probiotic mix was demonstrated as safe; however,
no difference in efficacy was demonstrated between groups. In a placebo-controlled study, children
(n = 40; 9 ± 2.2 years of age) with allergic rhinitis and asthma received the same probiotic mix over a
four week period [41] and showed significant improvement of symptoms. In a DBRCT crossover trial,
children (8–16 years of age) with irritable bowel syndrome (IBS) (n = 48) and functional dyspepsia
(n = 25) received the same probiotic mix over a six week period [42]. Administration of probiotics
improved abdominal pain in children with IBS but not with functional dyspepsia. The proportion of IBS
children who reported an improvement in QoL (quality of life) was significantly higher after probiotics
than after placebo (48% vs. 17%). In a trial conducted in Japan (n = 44, six weeks old), low-birthweight
infants assigned to a modified probiotic mix of M63, M16, and BB536 (500 million CFU/day of each
strain) over a six week feeding period demonstrated higher bifidobacteria GI colonization compared
to those receiving M16 alone [43]. The above studies used a probiotic mix including B. infantis M63.
Although the benefits cannot be directly attributed exclusively to B. infantis, the results are in agreement
with several mechanisms of B. infantis described above.
2.3.2. B. infantis ATCC 15697
A study by Underwood et al. [44] consisted of two phases; in phase one, premature infants (n = 12,
five weeks old) received formula feedings and were randomized to receive B. infantis ATCC 15697
(4 billion CFU twice daily) or B. animalis subsp. lactis with doses increased over a five week feeding
period. In phase two, nine premature infants receiving their mother’s milk received each of those two
bifidobacteria for two weeks separated by a one-week washout period. Fecal bifidobacteria count
was significantly higher and, in case of phase two, Proteobacteria were significantly lower in the ATCC
15697 group, with authors concluding that ATCC 15697 was more effective at colonizing the premature
infants compared to B. animalis sbsp. lactis [44]. The study also demonstrated that the combination of
human milk and B. infantis was most effective at “normalizing” the fecal microbiota confirming the
specialized ability of B. infantis to metabolize HMO.
Infants with confirmed gastroschisis were enrolled (n = 24, gestational age at birth > 34 weeks)
in a placebo-controlled pilot study. Participants were randomized to receive either ATCC 15697
(1 billion CFU) or a placebo twice daily for six weeks or until hospital discharge [45]. ATCC 15697 was
well tolerated, even during the period of gastric suctioning. Infants fed B. infantis had higher fecal
Bifidobacteriaceae, lower Clostridiaceae, and trends toward lower Enterobacteriaceae, Enterococcaceae,
Staphylococcaceae, and Streptococcaceae. Clinical outcomes, including length of hospital stay did not
differ between groups.
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2.3.3. B. infantis UCD272
Children with autism spectrum disorders (ASD; n = 11, 2 to 11 years of age) and a history of
chronic constipation, diarrhea, or IBS were enrolled in a crossover study; participants received a
combination of B. infantis UCD272 (20 billion CFU/day; Culture Systems, Inc., Mishawaka, IN) and
a prebiotic (bovine colostrum product) over a five-week period, followed by a two-week washout,
and five weeks of prebiotic alone [46]. UCD272 was well tolerated; however, a trend toward greater
reduction in GI symptoms, aberrant behavior and immune imbalance was observed during use of the
prebiotic alone. Conclusions were limited due to the small number of participants enrolled.
2.3.4. B. infantis EVC001
Clinical outcomes related to B. infantis EVC001 in breastfed infants were described in several
recent publications. Mother/infant dyads (n = 80) were randomized by parallel assignment to either
lactation support (LS; Control) or LS + EVC001 (Evolve Biosystems, Davis, CA) over a 21-day feeding
period [47]. EVC001 was packaged in single-use sachets (156 mg; 18 billion CFU) and delivered diluted
with lactose starting at postnatal day (PND) seven [47]. Primary outcomes included health and safety
reporting (body temperature, GI symptom ratings, number of illnesses and sick doctor visits, use
of antibiotics or gas-relieving medications, presence of colic, jaundice, flatulence, or bloody stool)
and stool Bifidobacterium spp. counts from PND 6 to 28. Stool samples were collected through PND
60. In each group, 34 participants were included in the analysis. Stool Bifidobacterium spp. count
was significantly higher and stool frequency significantly lower in infants receiving EV0001 from
PND 6 to 28. No group differences in health and safety outcomes were detected. One month after
discontinuing feeding EVC001, stool count of EVC001 persisted and was significantly higher compared
to the control group [36]. The dominance of EVC001 influenced beta diversity (diversity between
samples); however, there were no differences in terms of microbial species richness (alpha diversity) as
the Shannon diversity index was similar between Control and EVC001 groups. Lack of differences in
alpha diversity between Control and EVC001 is consistent with previous reports on breast-fed infants.
Recently, lower alpha diversity was reported in infants receiving human milk compared to infant
formula [59]. In addition, stool HMO from PND 6 to 29 were significantly lower (suggesting increased
bifidobacteria metabolism) in the EVC001 group compared to the control group; acetate and lactate
were significantly higher in the EVC001 vs. the control group. Increased production of lactate and
acetate alters the intestinal environment to prohibit the growth of pH-sensitive pathogenic populations
(e.g., Enterobacteriaceae and Clostridia). Specifically, average fecal pH was 5.15 in infants colonized
by EVC001, compared to 5.97 fecal pH and 10-fold higher fecal HMO in infants lacking EVC001
colonization [36]. Stool endotoxins were 4-fold lower in the EVC001 group, consistent with observed
lower levels of Gram-negative Proteobacteria and Bacteroidetes. The relative abundance of virulent
pathogens such as E. coli, Klebsiella, Clostridium and Staphylocossus were decreased by over 93% [48].
Shotgun metagenomics was used to examine the effect of feeding EVC001 upon antibiotic resistance
genes (ARG, i.e., the resistome) in infants (Control, n = 31; EVC001, n = 29) from PND 7 to 21 [48].
The resistome is the collection of all the antibiotic resistance genes, including those associated with
pathogenic bacteria, non-pathogenic antibiotic producing bacteria, and all other resistance genes [60].
ARG are associated with resistance to a wide range of drugs including β-lactamase, fluoroquinolone,
and tetracycline. In the EVC001 group 87.5% fewer ARG were detected in the microbiome; 38 ARG
were significantly reduced, and relative and absolute abundance of Escherichia (which predominantly
harbored ARG) were also significantly reduced [48]. It is possible that infants with fewer ARG could be
less likely to exhibit resistance to a wider spectrum of drug classes, however clinical studies are needed
to confirm this theory. Further analyses indicated much less evidence of mucous layer erosion and
inflammation in infants in the EVC001 compared to the control group. Specifically, using nano-HPLC
chip/time-of-flight mass spectrometry, EVC001 was demonstrated to help maintain barrier function by
diminishing colonic glycan degradation [49]. In continuation of analyses conducted on the same cohort,
significantly more stool N-glycans (specific complex carbohydrates released from milk glycoproteins
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and available for select use by B. infantis) were measured in stool samples from the EVC001 group.
The release of selectively fermentable N-glycans may increase the prebiotic activity and increase
the growth of EVC001 in vivo. Finally, in stool samples from the same cohort, significantly lower
calprotectin and proinflammatory cytokines were reported in infants receiving EVC001 [50] suggesting
lower enteric inflammation.
2.3.5. B. infantis CECT 7210
Term infants (<3 months of age) enrolled in a multicenter DBRCT were randomized to receive a
standard IF (Control, n = 97) or IF with added B. infantis CECT 7210 at 10 million CFU per 100 mL
formula (Laboratorio Ordesa SL, Spain) (n = 93) for a 12-week feeding period [51]. Parent-reported
incidence of diarrhea was the primary outcome. Secondary outcomes included incidence of infection,
salivary IgA levels, stool microbiota, infant growth, and tolerance measures. A total of 151 infants
completed the study (Control, n = 78; CECT 7210, n = 73). Overall diarrhea events per infant (median;
Control: 0.29 ± 1.07, CECT 7210: 0.05 ± 0.28) were not significantly different between groups. Stool
frequency was significantly lower in the control group after four weeks of study feeding. By study
end, total stool Bifidobacterium spp. was similar between groups; however, B. infantis was significantly
higher in the CECT7210 group. No differences in growth, formula intake, or other secondary outcomes
were observed. Overall, the authors concluded that formula with added CECT was safe, effective,
and well tolerated in healthy term infants.
2.3.6. B. infantis BB02
Jacobs and colleagues studied a mix of three probiotics, including the strain B. infantis BB02
in preterm infants (<32 completed weeks of gestation, 1500 g or less) enrolled in a multicenter
DBRCT. Infants were randomized to receive daily administration of a probiotic combination (BB02,
Streptococcus thermophilus TH4, and B. lactis BB12; 1 billion CFU/day; Solgar, NJ, USA; n = 548) or
a placebo (maltodextrin; n = 551) [52]. The primary outcome was at least one episode of definite
late-onset sepsis. Incidence of NEC (Bell stage 2 or higher) was significantly reduced in infants receiving
the probiotic combination; no group difference in definite late-onset sepsis or all-cause mortality
was detected. Stool microbiome analysis of the study cohort demonstrated significantly increased
Bifidobacterium spp. count and reduced genus Enterococcus count in infants who received probiotics [53].
Considering that this probiotic combination included other probiotic strains in addition to B. infantis,
the observed benefits cannot be attributed definitively to BB02. However, the observed increase in
Bifidobacterium spp. and reduction in NEC are consistent with the mechanisms we described above,
e.g., increase of beneficial microbiota and improvement of gut barrier integrity.
2.3.7. B. infantis R0033
Healthy term infants were enrolled (n = 208; 3 to 12 months of age) and received B. infantis
R0033 (3 billion CFU/d; Lallemand Health Solutions, Montreal, Canada) over an eight week feeding
period [54]. Other study groups included L. helveticus and B. bifidum. R0033 was safe, well tolerated,
and had no impact on growth (weight, height, and head circumference). A significant decrease
in fecal Blautia, Collinsella, Enterococcus and Klebsiella genera and increase in the IL-10/IL-12 ratio
were demonstrated in infants receiving R0033, suggesting anti-pathogenic and anti-inflammatory
activity [55]. The anti-inflammatory effect of R0033 can be potentially attributed to production of ILA
(see “Carbohydrate Metabolisms and SCFA Production” above), although ILA was not measured in
this study.
In another DBRCT, children three to seven years of age (n = 135) received a daily synbiotic
preparation (R0033, L. helveticus R0052, B. bifidum R0071 (3 billion CFU total), and fructo-oligosaccharide
(FOS)) over a three month feeding period [56]. Otherwise healthy, participants suffered from at least
three episodes of ear, nose and throat, respiratory tract, or GI illness during the previous winter.
Overall, supplementation with a probiotic mix, which included R0033, significantly decreased the
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risk of occurrence of common infectious diseases in children. No side effects were detected in either
group. As in several other studies listed in our review, the associated benefits cannot be exclusively
attributed to R003 alone. However, the decrease in infectious diseases, including GI illnesses is
supported by well-described mechanisms of B. infantis, which include prohibition of pH-sensitive
pathogenic organisms.
2.3.8. B. infantis BT1
Term infants were enrolled (n = 106, newborn) in a DBRCT; participants received a control IF or IF
with an added probiotic mix of B. infantis BT1, B. bifidum BF3, B. breve BR3, and B. longum BG7 (total
10 million CFU/g) through 12 months of age to measure fecal microbiota diversity and composition [57].
Although Bacteroides and Blautia spp. counts were lower after one month of feeding in infants receiving
probiotics, no group differences in microbiome or metabolite profile were detected after 12 months
of age. No significant differences were observed between infant feeding groups regarding growth,
antibiotic uptake, or other health variables.
3. Conclusions
Studies reviewed in this manuscript suggest that colonization with B. infantis might have potential
beneficial effects in infants and children. B. infantis is well adapted to the infant gut, in part due
to its ability to consume complex carbohydrates found in human milk (HMO). As evidenced in
clinical studies, the administration of B. infantis leads to successful colonization in the gut, where the
highly selective and acidic fermentation of HMO results in increased production of lactate and acetate,
and subsequent reduction of gut dysbiosis and lower pH. This potentially includes an important role
in development and maturation of the immune system. Modern practices, including C-section and
perinatal antibiotics have disrupted the mother-to-infant transfer of B. infantis at birth, leading to a
loss of this key member of the infant gut microbiota, which has resulted in an increase of stool pH in
infants [13]. Continuing to gather evidence of the protective effects of B. infantis strains within the
infant gut will help us better understand the critical role of the infant gut microbiome in establishing
long-term health.
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